A method for controlled crystallization preparation of stable crystal form of derafloxacin meglumine salt

By employing a staged antisolvent crystallization and continuous reflux of the ethyl acetate phase followed by reduced-pressure azeotropic dehydration, combined with the steric hindrance and seed guidance of polyvinylpyrrolidone K17, the problems of liquid-liquid phase separation and poor powder flowability in the crystallization of derafloxacin meglumine salt were solved, achieving the preparation of a stable crystal form with high purity and uniform particle size.

CN123106631APending Publication Date: 2026-11-17JINAN KEHUI MEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611447526.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-17
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The existing crystallization process for derafloxacin meglumine salt is prone to liquid-liquid phase separation, resulting in mixed crystal forms. The fine crystals encapsulate impurities and moisture, causing difficulties in solid-liquid separation and poor powder flowability after drying.

Method used

A staged antisolvent crystallization and continuous reflux of ethyl acetate phase were used for depressurized azeotropic dehydration. The steric hindrance of polyvinylpyrrolidone K17 was combined to control the antisolvent droplet acceleration rate to match the crystal surface area. Target stable crystal form micronized seed crystals were added, and the solute was guided to grow in a directional manner through gas phase bubbling and linear cooling programs.

Benefits of technology

It improves product purity, enhances filtration performance and powder flowability, reduces impurity residue and crystal instability, and ensures the uniformity and stability of crystal particle size distribution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106631A_ABST
    Figure CN123106631A_ABST
Patent Text Reader

Abstract

This application relates to the field of pharmaceutical compound synthesis and crystallization technology, and discloses a controllable crystallization preparation method for a stable crystal form of derafloxacin meglumine salt. The method involves mixing dimethyl sulfoxide with purified water, adding derafloxacin free acid and meglumine, dissolving it with polyvinylpyrrolidone K17, and then dropwise adding a first portion of ethyl acetate. When opalescence appears, micronized seed crystals are added. Subsequently, the remaining ethyl acetate is added non-linearly according to a cubic function of time. Nitrogen gas is then bubbled and azeotropic dehydration is performed under reduced pressure. The aqueous phase is discharged, and the ethyl acetate phase is refluxed to maintain the liquid level. Finally, the product is obtained by cooling, solid-liquid separation, washing, and drying. This invention alleviates gas-liquid phase separation and secondary nucleation by adding an auxiliary agent and non-linearly adding an antisolvent; combined with azeotropic dehydration, solvent residue is reduced, improving the crystal purity and powder flowability of the product, and solving the problems of uncontrollable nucleation and difficult separation in existing processes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical compound synthesis and crystallization technology, specifically to a method for the controlled crystallization preparation of a stable crystal form of derafloxacin meglumine salt. Background Technology

[0002] Delafloxacin is a broad-spectrum fluoroquinolone antibacterial drug. Its solubility and bioavailability in water can be improved by forming a salt with meglumine. In the industrial production of pharmaceuticals, the crystal structure, morphology, and particle size distribution of the active pharmaceutical ingredient directly affect its physicochemical stability, dissolution rate, and the processing performance of downstream formulations. Therefore, obtaining high-purity, uniformly sized, and crystal-stable delafloxacin meglumine salt crystals is a crucial step in the preparation of this compound.

[0003] Existing crystallization processes for derafloxacin meglumine salt mostly employ conventional cooling crystallization or simple antisolvent crystallization methods. In practice, due to the drastic changes in the solubility of this salt compound in a mixture of good and antisolvent systems, the supersaturation of the system is often difficult to maintain, leading to liquid-liquid phase separation, commonly known as oil separation, in the early stages of crystallization. This phase separation causes the solute in the system to spontaneously aggregate into high-concentration solute-rich droplets, disrupting the normal thermodynamic environment for crystallization. This results in uncontrollable nucleation processes, easily leading to polymorphism mixing and a decrease in the purity of the target stable crystal form.

[0004] Meanwhile, traditional linear dropwise addition of antisolvents often leads to a rapid increase in local supersaturation beyond the metastable region, triggering numerous secondary nucleations. This results in fine crystal particles with a wide particle size distribution and irregular morphology. These fine, flocculent powders easily trap water and impurities in the crystallization mother liquor, increasing filtration resistance in subsequent solid-liquid separation stages and making washing difficult. Due to the significant amount of residual water inside or on the surface of the crystal clusters, conventional drying methods are insufficient for deep removal. This not only affects the stability of the crystal form during storage but also causes the dried powder to easily adhere and aggregate, resulting in a large angle of repose and poor flowability, which inconveniences subsequent formulation processing steps. Summary of the Invention

[0005] To address the shortcomings of existing technologies, this invention provides a controllable crystallization preparation method for a stable crystal form of derafloxacin meglumine salt. This method solves the problems of liquid-liquid phase separation leading to mixed crystal forms in conventional crystallization processes, as well as the difficulty in solid-liquid separation caused by impurities and moisture encapsulated in fine crystals, and the poor flowability of the powder after drying.

[0006] To achieve the above objectives, the present invention provides the following technical solution: This invention provides a method for the controlled crystallization preparation of a stable crystal form of derafloxacin meglumine salt, comprising the following steps: (1) Mix dimethyl sulfoxide with purified water evenly, add delafloxacin free acid and meglumine, heat and stir at a constant temperature until a clear homogeneous solution is formed; then add polyvinylpyrrolidone K17 and continue stirring to dissolve polyvinylpyrrolidone K17. (2) Maintain the system temperature of step (1), add the first part of ethyl acetate antisolvent to the reactor at a constant flow rate until the system appears opalescent, add the target stable crystal form micronized seed crystal of derafloxacin meglumine salt, stop adding antisolvent and carry out constant temperature crystal growth; (3) Maintain the system temperature and add the remaining second part of ethyl acetate dropwise through a nonlinear antisolvent dropwise program. Control the ratio of the cumulative volume of the second part of ethyl acetate added to the total volume of the second part of ethyl acetate added to be equal to the cube of the ratio of the current dropwise time of the second part of ethyl acetate to the total dropwise time of the second part of ethyl acetate. (4) After the addition is completed, nitrogen gas is continuously introduced from the bottom of the reactor to bubble the gas phase, while the pressure inside the reactor is gradually reduced to a vacuum state, so that the system undergoes depressurized azeotropic dehydration; after the azeotropic vapor is condensed and separated by a water separator, the bottom water phase is discharged, and the upper ethyl acetate phase is continuously refluxed into the reactor to maintain a constant liquid level in the system. When the mass fraction of water in the liquid phase in the reactor drops to 0.10wt% to 0.25wt%, the vacuum is released. (5) The system is linearly cooled to the set temperature and kept at that temperature. Then the suspension slurry is separated into solid and liquid, the filter cake is washed, and finally dried to obtain the target stable crystal form of derafloxacin meglumine salt.

[0007] By adopting the above technical solution, and through the use of staged anti-solvent crystallization and continuous reflux of the ethyl acetate phase in a reduced-pressure azeotropic dehydration process, the effects of improved product purity, stable crystal form, and enhanced filtration performance and powder flowability are achieved. The specific working principle is explained step by step as follows: In step (1), the carboxyl group in the free acid of derafloxacin undergoes a proton transfer reaction with meglumine to form derafloxacin meglumine salt. Dimethyl sulfoxide and purified water are used as a good mixed solvent to facilitate the reaction. After dissolving, polyvinylpyrrolidone K17 forms steric hindrance in the solution, which helps to increase the width of the metastable region of the solution, thereby reducing the liquid-liquid phase separation phenomenon caused by spontaneous aggregation of solute in high-concentration systems.

[0008] In step (2), ethyl acetate is added at a constant flow rate to establish initial supersaturation, causing the system to enter the lower limit of the metastable region and exhibit an opalescent state. Delafloxacin meglumine salt is then added to create micronized seed crystals of the target stable crystal form, providing nucleation sites with low energy barriers directly from the seed crystal surface. Solute molecules grow directionally on the seed crystal surface according to the target lattice arrangement, reducing the probability of polymorphic coexistence and flocculent fine powder problems caused by spontaneous nucleation.

[0009] In step (3), the crystal growth rate is positively correlated with the total crystal surface area. When adding the second portion of ethyl acetate, the cumulative added volume is controlled to increase according to a cubic function of time, so that the addition rate of ethyl acetate matches the growth trend of the crystal surface area. This mechanism helps to maintain the supersaturation of the system within the metastable region, alleviates secondary nucleation caused by local supersaturation surges, and is beneficial to the enlargement of crystal grain size.

[0010] In step (4), nitrogen gas is continuously introduced into the bottom to generate a large number of tiny bubbles, providing a continuous gas-liquid interface for depressurization vaporization, alleviating the metastable superheated state of the liquid, and reducing the occurrence of boiling and surging during the dehydration process. Ethyl acetate forms a low-boiling-point azeotropic system with water in the system. After depressurization evaporation and condensation into layers, the aqueous phase is discharged independently to remove water.

[0011] The continuous reflux of the upper ethyl acetate phase helps maintain a constant total fluid volume within the reactor, reducing the risk of increased supersaturation caused by volume shrinkage due to solvent evaporation. Simultaneously, the refluxed ethyl acetate, in a boiling fluid state, exerts a scouring and shearing effect on the surface of the suspended crystals, causing the adsorbed polyvinylpyrrolidone K17 to physically desorb and redissolve in the mother liquor, thus reducing the residual high-molecular-weight impurities in the product.

[0012] In step (5), linear cooling further reduces the solute solubility to complete crystallization. The regularly growing crystal clusters form interconnected pore channels in the solid-liquid separation process, which helps to reduce filtration resistance. The washing and vacuum drying processes further remove the mother liquor and residual solvent, which is beneficial to obtaining dry powder with a small angle of repose and good flowability.

[0013] Preferably, in step (1), for every 100g of derafloxacin free acid added, the amount of dimethyl sulfoxide added is 425g to 600g, the amount of purified water added is 75g to 200g, the amount of meglumine added is 44.8g to 46.5g, and the amount of polyvinylpyrrolidone K17 added is 0.1g to 0.3g; the heating rate is 1.5℃ / min to 2.0℃ / min, the constant temperature stirring temperature is 60℃ to 70℃, the constant temperature stirring time is 1.0h to 2.0h, and the stirring time after adding polyvinylpyrrolidone K17 is 20min to 40min.

[0014] By adopting the above technical solution, controlling the solvent ratio and heating conditions is beneficial to the salt formation reaction. The amount of polyvinylpyrrolidone K17 added is set in an appropriate range, which not only provides a certain spatial shielding effect to suppress oil phase separation, but also reduces the impact of excessive system viscosity on mass and heat transfer processes.

[0015] Preferably, in step (2), for every 100g of derafloxacin free acid added, the volume of the first part of ethyl acetate antisolvent added is 120mL to 600mL, the constant flow rate is 2.5mL / min to 6.6mL / min, the amount of derafloxacin meglumine salt target stable crystal micronized seed added is 0.7g to 2.8g, and the constant temperature crystal growth time is 1.5h to 3.0h.

[0016] By employing the above technical solution, limiting the dropwise flow rate and volume of the first batch of ethyl acetate helps the system slowly enter the metastable region. The amount of seed crystals added and the crystal growth time provide a certain initial growth period, which is beneficial for subsequent induced growth.

[0017] Preferably, in step (3), for every 100g of derafloxacin free acid added, the total volume of the second part of ethyl acetate added is 1080mL to 2400mL, and the total dropping time of the second part of ethyl acetate is controlled to be 3.0h to 5.0h; the cumulative volume of the second part of ethyl acetate added = the total volume of the second part of ethyl acetate added × (the current dropping time of the second part of ethyl acetate ÷ the total dropping time of the second part of ethyl acetate) 3 .

[0018] By adopting the above technical solution, the total amount of ethyl acetate in the second part and the cubic function dropping model are limited, so that the solvent mixing rate matches the three-dimensional volume expansion rate of the target crystal, thereby reducing the probability of the appearance of amorphous fine powder caused by spontaneous nucleation.

[0019] Preferably, in step (4), the continuous nitrogen flow rate is controlled to be 0.02vvm to 0.10vvm, the rate of gradual pressure reduction in the reactor is controlled to be 1.0kPa / min to 3.0kPa / min, the absolute pressure range maintained during the depressurized azeotropic dehydration process is 60kPa to 70kPa, and the set endpoint for the liquid phase water content is 0.10wt% to 0.25wt%.

[0020] By employing the above technical solution, the combined effect of trace nitrogen bubbling and a gradual depressurization rate helps maintain a stable thermodynamic and hydrodynamic environment. Controlling the dehydration endpoint facilitates the removal of water from the product lattice and reduces crystal structure transformations caused by excessive dehydration.

[0021] Preferably, in step (5), the linear cooling rate of the system is 5℃ / h to 15℃ / h, the set temperature is 0℃ to 10℃, and the holding time is 1.0h to 2.0h; for every 100g of derafloxacin free acid added, the filter cake is washed with 200mL to 500mL of cold ethyl acetate each time, and the number of washing times is 2 to 3; the drying is carried out under vacuum at a temperature of 40℃ to 50℃, with an absolute pressure of less than 5kPa, and the vacuum drying time is 6.0h to 10.0h.

[0022] By adopting the above technical solution, linear cooling at a rate of 5℃ / h to 15℃ / h can alleviate the thermal stress caused by sudden temperature drops and reduce the occurrence of cracks and delamination on the crystal surface. The combination of cold solvent displacement washing and vacuum drying helps to reduce the solvent residue and moisture content in the final product.

[0023] Preferably, the median particle size D50 of the micronized seed crystals of the target stable crystal form of derafloxacin meglumine salt in step (2) is 5.2 μm to 12.8 μm; The median particle size D50 of the micronized seed crystals of the target stable crystal form of derafloxacin meglumine salt was determined using a laser particle size analyzer and a dry powder injection module. The dispersion pressure was 0.15 MPa, the feed rate of the sampler vibrating disk was 50%, and the airflow shading was controlled at 2% to 8%. D50 was extracted from the volume-based particle size distribution data. The preparation steps of the target stable crystal form micronized seed crystals of derafloxacin meglumine salt include: Dimethyl sulfoxide was mixed evenly with purified water, and then derafloxacin free acid and meglumine were added. The mixture was stirred at a constant temperature of 60°C to 70°C until a clear homogeneous solution was formed. Under constant temperature and constant stirring speed, ethyl acetate was added dropwise to a homogeneous solution at a uniform rate. After the addition was completed, the cooling rate was controlled at 5℃ / h to 15℃ / h. The temperature was lowered to 0℃ to 10℃ and kept at the temperature while stirring to obtain a suspension. The suspension was centrifuged to separate the solid and liquid phases, dried, and pulverized to obtain micronized seed crystals of the target stable crystal form of derafloxacin meglumine salt.

[0024] Preferably, the suspension is centrifuged to separate solid and liquid components, and the filter cake is washed with cold ethyl acetate at a temperature of 0°C to 10°C. The washed filter cake was continuously vacuum dried at 40℃ to 50℃ and absolute pressure below 5kPa for 8.0h to 12.0h; the vacuum-dried material was transferred to a pulverizing device for micronization treatment, and the pulverized micronized powder was collected to obtain the micronized seed crystals of the target stable crystal form of derafloxacin meglumine salt.

[0025] By employing the above-mentioned technical solution, seed crystals are prepared using a physical crystallization method combining constant-rate dropping and programmed cooling. The absence of polyvinylpyrrolidone (K17) during the preparation process helps maintain the purity of the seed crystals. Controlling the median particle size within a defined range ensures that the crystal powder possesses suitable surface area and surface energy, reducing the risk of localized ablation in solution due to excessively small seed crystal size, or insufficient nucleation surface area due to excessively large size.

[0026] This invention provides a controlled crystallization method for preparing a stable crystal form of derafloxacin meglumine salt. It has the following beneficial effects: 1. This invention adds polyvinylpyrrolidone K17 to the salt-forming system and controls the addition of the second portion of ethyl acetate in a cubic function of time after crystal growth, so that the rate of antisolvent addition matches the growth trend of crystal surface area. This solvent mixing procedure, combined with the steric hindrance of polyvinylpyrrolidone K17, helps maintain the supersaturation of the system within the metastable region, reduces liquid-liquid phase separation caused by spontaneous aggregation of solute at high concentrations and secondary nucleation caused by local supersaturation, thereby improving the purity of the product crystal form and the uniformity of particle size distribution.

[0027] 2. This invention employs a combination of bottom-introduction of nitrogen gas-phase bubbling and reduced-pressure azeotropic dehydration, along with continuous reflux of the upper ethyl acetate phase. Nitrogen bubbling provides a stable gas-liquid interface for reduced-pressure vaporization, alleviating the metastable superheated state of the system and reducing bumping. The continuous reflux of ethyl acetate maintains a constant total fluid volume within the reactor, reducing the risk of increased supersaturation due to solvent evaporation. Furthermore, the boiling reflux fluid physically scours and shears the crystal surface, facilitating the desorption and redissolution of polyvinylpyrrolidone K17 adsorbed on the crystal surface, thus reducing impurity residues in the crystalline product.

[0028] 3. This invention provides low-barrier nucleation sites by adding micronized seed crystals of a target stable crystal form when opalescence occurs. Combined with a linear cooling program at the end of crystallization, this guides solute molecules to grow in a directional and orderly manner on the seed crystal surface. This process reduces thermal stress and surface morphology defects caused by sudden temperature drops, allowing regularly grown crystal clusters to form interconnected pore channels during solid-liquid separation. This reduces resistance during washing and filtration, while also improving the angle of repose and overall flowability of the dried powder product. Attached Figure Description

[0029] Figure 1 This is a comparison of the full X-ray powder diffraction spectra of the derafloxacin meglumine salt products obtained in Example 1 and Comparative Example 1 of the present invention. Figure 2 The above are comparison graphs of online process parameter monitoring during the crystallization process of Example 1 and Comparative Example 2 of the present invention. Among them, (a) is a graph of the change of stirring shaft torque with time, and (b) is a graph of the change of system transmittance with time. Figure 3 This is a comparison diagram of the volume-based particle size distribution of the derafloxacin meglumine salt products obtained in Example 1 and Comparative Example 3 of the present invention. Figure 4 This is a comparison of the visible absorption spectra of the derafloxacin meglumine salt products obtained in Example 1, Comparative Example 1, and Comparative Example 4 of the present invention. Figure 5The diagram shows a comparison of the process operating parameters of Example 1 and Comparative Example 5 during the decompression azeotropic dehydration stage of the present invention. (a) is a graph showing the change of absolute pressure in the reactor over time, and (b) is a graph showing the change of material temperature in the reactor over time. Figure 6 The figures show a comparison of the filtration performance and powder engineering properties of the products obtained in Examples 1 to 5 and Comparative Examples 1 to 5 of the present invention. Among them, (a) is a comparison of the filtration time per unit volume of slurry, (b) is a comparison of the weight loss of filter cake at 105°C, and (c) is a comparison of the angle of repose of dried powder. Detailed Implementation

[0030] The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0031] The main raw materials and reagents used in the following examples and comparative examples have the following sources and specifications. Reagents not specifically mentioned are all commercially available analytical grade or higher grade products.

[0032] The chemical name of derafloxacin free acid is 1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-7-(3-hydroxyazacyclobut-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, with the molecular formula C2. 18 H 12 ClF3N4O4, CAS number 189279-58-1, with a purity of not less than 99.0 wt%, is a conventional compound precursor with a clearly known chemical structure in the art.

[0033] The chemical name of meglumine is 1-deoxy-1-(methylamino)-D-sorbitol, and its molecular formula is C7H. 17 NO5, CAS number 6284-40-8, with a purity of not less than 99.0 wt%, is a conventional salt-forming reagent with a known structure in the art.

[0034] Polyvinylpyrrolidone K17 is a commercially available pharmaceutical excipient grade or industrial grade linear homopolymer with CAS number 9003-39-8. This polymer is generated by free radical polymerization of 1-vinyl-2-pyrrolidone monomer, with a weight-average molecular weight (Mw) between 7,000 and 11,000 and a K value between 15 and 18.

[0035] Preparation Example 1: This preparation example provides a method for preparing micronized seed crystals of the target stable crystal form of derafloxacin meglumine salt, including the following steps: (1) Add 640.0g of dimethyl sulfoxide and 160.0g of purified water into the reaction vessel and mix them evenly. Turn on the stirring and add 100.0g of derafloxacin free acid and 45.5g of meglumine in sequence. Heat the reaction system to 65℃ and maintain stirring for 1.0h until the salt formation reaction is complete and the system forms a completely clear homogeneous solution.

[0036] (2) Under constant temperature of 65℃ and stirring speed of 200 rpm, 2500 mL of ethyl acetate was added dropwise to the above clear homogeneous solution at a constant flow rate of 25 mL / min. After the addition was completed, the temperature was lowered to 5℃ at a rate of 10℃ / h, and the system was kept at 5℃ and stirred for 2.0 h.

[0037] (3) The suspension in the system was centrifuged to separate solid and liquid. The filter cake was washed with 300 mL of cold ethyl acetate at 5 °C. The washed filter cake was then placed in a vacuum drying device and dried continuously for 10.0 h at 45 °C and an absolute pressure of less than 5 kPa.

[0038] (4) The dried solid block was transferred to an air jet mill for micronization. The micronized powder was collected and its median particle size D50 was measured to be 10.5 μm. It was confirmed as the target stable crystal form by X-ray powder diffraction test. It was sealed and stored in the dark as a seed crystal for later use.

[0039] Preparation Example 2: This preparation example provides a method for preparing micronized seed crystals of small-particle-size derafloxacin meglumine salt with a target stable crystal form, including the following steps: (1) Add 320.0g of dimethyl sulfoxide and 80.0g of purified water into the reaction vessel and mix them evenly. Turn on the stirring and add 50.0g of derafloxacin free acid and 22.8g of meglumine in sequence. Heat the reaction system to 60℃ and maintain stirring for 1.5h until the system forms a completely clear homogeneous solution.

[0040] (2) Under constant temperature of 60℃ and stirring speed of 300rpm, 1200mL of ethyl acetate was rapidly added dropwise to the above clear homogeneous solution at a constant flow rate of 50mL / min. After the addition was completed, the temperature was lowered to 0℃ at a rate of 15℃ / h, and the system was kept at 0℃ and stirred for 1.0h.

[0041] (3) The suspension in the system was centrifuged to separate solid and liquid. The filter cake was washed with 150 mL of cold ethyl acetate at 0 °C. The washed filter cake was then placed in a vacuum drying device and dried continuously for 12.0 h at 40 °C and an absolute pressure of less than 5 kPa.

[0042] (4) The dried solid block was transferred to a mechanical grinder for micronization. The pulverized powder was collected and its median particle size D50 was measured to be 5.2 μm. X-ray powder diffraction test confirmed it as the target stable crystal form. It was sealed and stored in the dark as a seed crystal for later use.

[0043] Preparation Example 3: This preparation example provides a pilot-scale method for preparing micronized seed crystals of the target stable crystalline form of derafloxacin meglumine salt, comprising the following steps: (1) Add 6.4 kg of dimethyl sulfoxide and 1.6 kg of purified water into a 50 L crystallization reactor and mix them evenly. Turn on the stirring and add 1.0 kg of derafloxacin free acid and 0.455 kg of meglumine in sequence. Heat the reaction system to 70 °C and maintain stirring for 1.5 h until the system forms a completely clear homogeneous solution.

[0044] (2) Under constant temperature of 70℃ and stirring speed of 150rpm, 25.0L of ethyl acetate was added dropwise to the above clear homogeneous solution at a constant flow rate of 250mL / min. After the addition was completed, the temperature was lowered to 10℃ at a rate of 5℃ / h, and the system was kept at 10℃ and stirred for 3.0h.

[0045] (3) The suspension in the system was discharged into the lower discharge centrifuge for separation. The filter cake was washed with 3.0L of cold ethyl acetate at 10℃. The washed filter cake was then placed in a double cone vacuum dryer and dried continuously for 8.0h at 50℃ and an absolute pressure of less than 5kPa.

[0046] (4) The dried solid material was transferred to an industrial-grade air jet mill for micronization. The micronized powder was collected and its median particle size D50 was measured to be 12.8 μm. X-ray powder diffraction test confirmed it as the target stable crystal form. It was sealed with nitrogen and stored in the dark as a seed crystal for later use.

[0047] Example 1: This embodiment provides a method for the controlled crystallization preparation of a stable crystal form of derafloxacin meglumine salt, comprising the following steps: (1) Add 560.0g of dimethyl sulfoxide and 140.0g of purified water to a crystallization reactor equipped with a DCS control system, a bottom gas distributor, a condenser, and a water separator. Turn on the stirring and set the speed to 100rpm. Add 100.0g of derafloxacin free acid and 45.5g of meglumine in sequence. Raise the temperature inside the reactor to 65℃ at a rate of 2℃ / min and stir at a constant temperature for 1.0h until the system is a completely clear homogeneous solution. Then add 0.20g of polyvinylpyrrolidone K17 powder and continue stirring at 65℃ for 30min.

[0048] (2) Maintain the reactor temperature at 65°C and add 300 mL of ethyl acetate dropwise to the reactor at a constant flow rate of 5 mL / min. After a total of 300 mL of ethyl acetate has been added, the system exhibits a slight opalescence. At this point, add 1.5 g of the micronized seed crystals of the target stable crystal form of derafloxacin meglumine obtained in Preparation Example 1. Stop adding the antisolvent and maintain the temperature at 65°C for 2.0 h to allow crystal growth.

[0049] (3) Maintain the temperature of the kettle at 65°C and add the remaining 1700 mL of ethyl acetate through the nonlinear antisolvent addition program set by the DCS system. The cumulative volume of the second part of ethyl acetate added increases according to the cubic function of the second part of ethyl acetate addition time. The corresponding instantaneous addition flow rate gradually increases with the addition time. The total addition time of the second part of ethyl acetate is controlled to be 4.0 h.

[0050] (4) After the addition is complete, maintain the reactor temperature at 65°C and continuously introduce nitrogen gas through the bottom gas distributor at a flow rate of 0.05 vvm. Slowly reduce the reactor pressure at a rate of 2.0 kPa / min using the vacuum regulating system until the absolute pressure drops to 65 kPa. Then, perform depressurized azeotropic dehydration with nitrogen-assisted bubbling and ethyl acetate phase reflux. The azeotropic vapor, after condensation, enters the water separator for natural stratification. The bottom aqueous phase is discharged from the system, while the upper ethyl acetate phase is continuously refluxed back into the reactor through the overflow port. When the bottom of the water separator no longer continuously precipitates an independent aqueous phase, and a sample of the liquid phase in the reactor is taken and tested, showing a water content of 0.15 wt%, release the vacuum, stop the nitrogen supply, and restore atmospheric pressure.

[0051] (5) The temperature of the reactor was linearly reduced from 65℃ to 5℃ at a rate of 10℃ / h and held at that temperature for 1.5h. The slurry in the system was discharged into a centrifuge for solid-liquid separation. The filter cake was washed twice with 400mL of cold ethyl acetate at 5℃. The washed filter cake was then continuously vacuum dried at 45℃ and an absolute pressure of less than 5kPa for 8.0h to obtain the target stable crystalline product of derafloxacin meglumine salt.

[0052] Example 2: This embodiment provides a method for the controlled crystallization preparation of a stable crystal form of derafloxacin meglumine salt, comprising the following steps: (1) Add 425.0g of dimethyl sulfoxide and 75.0g of purified water to a crystallization reactor equipped with a DCS control system, a bottom gas distributor, a condenser, and a water separator. Turn on the stirring and set the speed to 120rpm. Add 100.0g of derafloxacin free acid and 44.8g of meglumine in sequence. Raise the temperature inside the reactor to 60℃ at a rate of 1.5℃ / min and stir at a constant temperature for 1.0h until the system is a completely clear homogeneous solution. Then add 0.10g of polyvinylpyrrolidone K17 powder and continue stirring at 60℃ for 20min.

[0053] (2) Maintain the reactor temperature at 60°C and add 120 mL of ethyl acetate dropwise to the reactor at a constant flow rate of 2.5 mL / min. After a total of 120 mL of ethyl acetate has been added, the system exhibits a slight opalescence. At this point, add 0.7 g of the micronized seed crystals of the target stable crystal form of derafloxacin meglumine obtained from Preparation Example 2. Stop adding the antisolvent and maintain the temperature at 60°C for 1.5 h to grow crystals.

[0054] (3) Maintain the temperature of the kettle at 60°C and add the remaining 1080 mL of ethyl acetate through the nonlinear antisolvent addition program set by the DCS system. The cumulative volume of the second part of ethyl acetate added increases according to the cubic function of the second part of ethyl acetate addition time. The corresponding instantaneous addition flow rate gradually increases with the addition time. The total addition time of the second part of ethyl acetate is controlled to be 3.0 h.

[0055] (4) After the addition is complete, maintain the reactor temperature at 60°C and continuously introduce nitrogen gas through the bottom gas distributor at a flow rate of 0.02 vvm. Slowly reduce the reactor pressure at a rate of 3.0 kPa / min using the vacuum regulating system until the absolute pressure drops to 60 kPa. Then, perform depressurized azeotropic dehydration with nitrogen-assisted bubbling and ethyl acetate phase reflux. The azeotropic vapor, after condensation, enters the water separator for natural stratification. The bottom aqueous phase is discharged from the system, while the upper ethyl acetate phase is continuously refluxed back into the reactor through the overflow port. When the bottom of the water separator no longer continuously precipitates an independent aqueous phase, and a sample of the liquid phase in the reactor is taken and its water content drops to 0.25 wt%, the vacuum is released, nitrogen supply is stopped, and atmospheric pressure is restored.

[0056] (5) The temperature of the reactor was linearly reduced from 60℃ to 0℃ at a rate of 15℃ / h and held at that temperature for 1.0h. The slurry in the system was discharged into a centrifuge for solid-liquid separation. The filter cake was washed twice with 200mL of cold ethyl acetate at 0℃. The washed filter cake was then continuously vacuum dried at 40℃ and an absolute pressure of less than 5kPa for 6.0h to obtain the target stable crystalline product of derafloxacin meglumine salt.

[0057] Example 3: This embodiment provides a method for the controlled crystallization preparation of a stable crystal form of derafloxacin meglumine salt, comprising the following steps: (1) Add 600.0g of dimethyl sulfoxide and 200.0g of purified water to a crystallization reactor equipped with a DCS control system, a bottom gas distributor, a condenser, and a water separator. Turn on the stirring and set the speed to 80rpm. Add 100.0g of derafloxacin free acid and 46.5g of meglumine in sequence. Raise the temperature inside the reactor to 70℃ at a rate of 2℃ / min and stir at a constant temperature for 2.0h until the system is a completely clear homogeneous solution. Then add 0.30g of polyvinylpyrrolidone K17 powder and continue stirring at 70℃ for 40min.

[0058] (2) Maintain the reactor temperature at 70°C and add 600 mL of ethyl acetate dropwise to the reactor at a constant flow rate of 6.6 mL / min. After a total of 600 mL of ethyl acetate has been added, the system exhibits a slight opalescence. At this point, add 2.8 g of the micronized seed crystals of the target stable crystal form of derafloxacin meglumine obtained in Preparation Example 1. Stop adding the antisolvent and maintain the temperature at 70°C for 3.0 h to allow the crystals to grow.

[0059] (3) Maintain the temperature of the kettle at 70°C and add the remaining 2400 mL of ethyl acetate through the nonlinear antisolvent addition program set by the DCS system. The cumulative volume of the second part of ethyl acetate added increases according to the cubic function of the second part of ethyl acetate addition time. The corresponding instantaneous addition flow rate gradually increases with the addition time. The total addition time of the second part of ethyl acetate is controlled to be 5.0 h.

[0060] (4) After the addition is complete, maintain the reactor temperature at 70°C and continuously introduce nitrogen gas through the bottom gas distributor at a flow rate of 0.10 vvm. Slowly reduce the reactor pressure at a rate of 1.0 kPa / min using the vacuum regulating system until the absolute pressure drops to 70 kPa. Then, perform depressurized azeotropic dehydration with nitrogen-assisted bubbling and ethyl acetate phase reflux. The azeotropic vapor, after condensation, enters the water separator for natural stratification. The bottom aqueous phase is discharged from the system, while the upper ethyl acetate phase is continuously refluxed back into the reactor through the overflow port. When the bottom of the water separator no longer continuously precipitates an independent aqueous phase, and a sample of the liquid phase in the reactor is taken and its water content drops to 0.10 wt%, the vacuum is released, nitrogen supply is stopped, and atmospheric pressure is restored.

[0061] (5) The temperature of the reactor was linearly reduced from 70℃ to 10℃ at a rate of 5℃ / h, and kept at this temperature for 2.0h. The slurry in the system was discharged into a centrifuge for solid-liquid separation. For every 100g of derafloxacin free acid added, the total amount of cold ethyl acetate used to wash the filter cake was 200mL to 500mL, and the washing was performed in 2 to 3 times. The washed filter cake was continuously vacuum dried at 50℃ and an absolute pressure of less than 5kPa for 10.0h to obtain the target stable crystalline product of derafloxacin meglumine salt.

[0062] Example 4: This embodiment provides a method for the controlled crystallization preparation of a stable crystal form of derafloxacin meglumine salt, comprising the following steps: (1) Add 480.0g of dimethyl sulfoxide and 120.0g of purified water to a crystallization reactor equipped with a DCS control system, a bottom gas distributor, a condenser, and a water separator. Turn on the stirring and set the speed to 90 rpm. Add 100.0g of derafloxacin free acid and 45.5g of meglumine in sequence. Raise the temperature inside the reactor to 62℃ at a rate of 1.5℃ / min and stir at a constant temperature for 1.5h until the system is a completely clear homogeneous solution. Then add 0.15g of polyvinylpyrrolidone K17 powder and continue stirring at 62℃ for 30min.

[0063] (2) Maintain the reactor temperature at 62°C and add 270 mL of ethyl acetate dropwise to the reactor at a constant flow rate of 4.5 mL / min. After a total of 270 mL of ethyl acetate has been added, the system exhibits a slight opalescence. At this point, add 1.0 g of the micronized seed crystals of the target stable crystal form of derafloxacin meglumine obtained in Preparation Example 1. Stop adding the antisolvent and maintain the temperature at 62°C for 2.0 h to allow crystal growth.

[0064] (3) Maintain the temperature of the kettle at 62°C and add the remaining 1530 mL of ethyl acetate through the nonlinear antisolvent addition program set by the DCS system. The cumulative volume of the second part of ethyl acetate added increases according to the cubic function of the second part of ethyl acetate addition time. The corresponding instantaneous addition flow rate gradually increases with the addition time. The total addition time of the second part of ethyl acetate is controlled to be 4.5 h.

[0065] (4) After the addition is complete, maintain the reactor temperature at 62°C and continuously introduce nitrogen gas through the bottom gas distributor at a flow rate of 0.08 vvm. Slowly reduce the reactor pressure at a rate of 2.5 kPa / min using the vacuum regulating system until the absolute pressure drops to 62 kPa. Then, perform depressurized azeotropic dehydration with nitrogen-assisted bubbling and ethyl acetate phase reflux. The azeotropic vapor, after condensation, enters the water separator for natural stratification. The bottom aqueous phase is discharged from the system, while the upper ethyl acetate phase is continuously refluxed back into the reactor through the overflow port. When the bottom of the water separator no longer continuously precipitates an independent aqueous phase, and a sample of the liquid phase in the reactor is taken and tested, showing a water content of 0.12 wt%, release the vacuum, stop the nitrogen supply, and restore atmospheric pressure.

[0066] (5) The temperature of the reactor was linearly reduced from 62℃ to 5℃ at a rate of 8℃ / h, and held at that temperature for 1.5h. The slurry in the system was discharged into a centrifuge for solid-liquid separation. The filter cake was washed twice with 300mL of cold ethyl acetate at 5℃. The washed filter cake was then continuously vacuum dried at 45℃ and an absolute pressure of less than 5kPa for 8.0h to obtain the target stable crystalline product of derafloxacin meglumine salt.

[0067] Example 5: This embodiment provides a method for the controlled crystallization preparation of a stable crystal form of derafloxacin meglumine salt, comprising the following steps: (1) Add 56.0 kg of dimethyl sulfoxide and 14.0 kg of purified water to a 1000 L industrial stainless steel reactor equipped with a DCS control system, a bottom gas distributor, a tubular condenser, and a large-capacity water separator. Start stirring and set the speed to 60 rpm. Add 10.0 kg of derafloxacin free acid and 4.55 kg of meglumine in sequence. Turn on the jacket temperature control and raise the temperature inside the reactor to 65 °C. Stir at this temperature for 1.5 h until the system is a completely clear homogeneous solution. Then add 20.0 g of polyvinylpyrrolidone K17 powder and continue to circulate and stir at 65 °C for 30 min.

[0068] (2) Maintain the reactor temperature at 65°C and add 30.0 L of ethyl acetate to the reactor at a constant flow rate of 0.5 L / min. After adding a total of 30.0 L of ethyl acetate, the system exhibits a slight opalescence. At this point, add 150.0 g of the target stable crystal form micronized seed crystals prepared on a pilot scale using the preparation example 3. Stop adding the antisolvent and maintain the temperature at 65°C for 2.0 h to grow crystals.

[0069] (3) Maintain the kettle temperature at 65°C, and add the remaining 170.0L of ethyl acetate through a nonlinear antisolvent addition program linked to the mass flow meter and the DCS system. The cumulative volume of the second part of ethyl acetate added increases according to the cubic function of the second part of ethyl acetate addition time. The corresponding instantaneous addition flow rate gradually increases with the addition time. The total addition time of the second part of ethyl acetate is controlled to be 4.0h.

[0070] (4) After the addition is complete, maintain the reactor temperature at 65°C and continuously introduce nitrogen gas through the bottom gas distributor at a flow rate of 0.05 vvm. Slowly reduce the reactor pressure at a rate of 2.0 kPa / min using a dry vacuum pump. When the absolute pressure drops to 65 kPa, the system undergoes nitrogen-assisted bubbling and ethyl acetate phase reflux under reduced pressure azeotropic dehydration. The azeotropic vapor is condensed in a tubular condenser and then enters the water separator for natural stratification. The bottom aqueous phase is automatically discharged through the bottom drain valve, while the upper ethyl acetate phase is continuously refluxed back into the reactor through a large-diameter overflow pipe. When the bottom of the water separator no longer continuously precipitates an independent aqueous phase, and a sample of the liquid phase in the reactor is taken and tested, and its water content drops to 0.15 wt%, the vacuum is released, nitrogen supply is stopped, and the pressure is restored to atmospheric pressure.

[0071] (5) The temperature of the reactor was linearly reduced from 65℃ to 5℃ at a rate of 10℃ / h and held at that temperature for 1.5h. The slurry in the system was discharged into a three-legged centrifuge through a closed pipeline for solid-liquid separation. The filter cake was sprayed and washed twice with 40.0L of cold ethyl acetate at 5℃. The washed filter cake was transferred to a double cone rotary vacuum dryer and continuously vacuum dried for 8.0h at 45℃ and an absolute pressure of less than 5kPa to obtain the industrial-scale prepared stable crystal form of derafloxacin meglumine salt.

[0072] Comparative Example 1: Compared with Example 1, the differences are as follows: in step (1), polyvinylpyrrolidone K17 powder is not added; after adding seed crystals and growing crystals at a constant temperature in step (2), the 1700 mL ethyl acetate in step (3) is not added using a non-linear anti-solvent dropping procedure, but is added using a constant flow rate, and the total dropping time is still 4.0 h; after the dropping is completed, step (4) is omitted, and the process proceeds directly to step (5) for cooling and crystallization. All other steps are the same as in Example 1.

[0073] Comparative Example 2: Compared with Example 1, the difference is that polyvinylpyrrolidone K17 powder is not added in step (1), while the rest is the same as in Example 1.

[0074] Comparative Example 3: Compared with Example 1, the difference is that in step (3), the remaining 1700 mL of ethyl acetate does not use the nonlinear antisolvent dropping procedure in which the cumulative volume of the second part of ethyl acetate increases according to the cubic function of the dropping time of the second part of ethyl acetate and the instantaneous dropping flow rate gradually increases with time. Instead, it uses a constant flow rate for dropping, and the total dropping time is still 4.0 h. Everything else is the same as in Example 1.

[0075] Comparative Example 4: Compared with Example 1, the difference is that after the addition of step (3), step (4) is omitted, that is, the nitrogen bubbling-assisted, ethyl acetate phase reflux dehydration under reduced pressure is not carried out, and the process directly proceeds to step (5) for programmed cooling crystallization. The rest is the same as Example 1.

[0076] Comparative Example 5: Compared with Example 1, the difference is that in step (4), the bottom gas distributor is not turned on to introduce nitrogen, and the water separator is not used to separate the condensate and reflux the ethyl acetate phase. Instead, the mixture of ethyl acetate and water vapor is directly vacuumed out until the mass fraction of water in the liquid phase in the reactor reaches the same dehydration endpoint as in Example 1. All other steps are the same as in Example 1.

[0077] Test Example 1: Test objective: To verify the crystal state and thermal characteristics of the products prepared in the embodiments and comparative examples of the present invention, and to confirm whether the present method can stably obtain the target stable crystal form with high relative crystallinity.

[0078] Experimental steps: (1) The dry powders prepared in Examples 1 to 5 and Comparative Example 1 were selected as test samples. Approximately 50 mg of each sample was taken and lightly ground in an agate mortar to eliminate the electrostatic agglomeration of the powder.

[0079] (2) Take about 10 mg of the ground sample, spread it evenly in the groove of the quartz sample holder, flatten the surface, and place it in the sample chamber of the X-ray powder diffractometer. Set the Cu-Kα radiation source, tube voltage of 40 kV, tube current of 40 mA, scanning range 2θ of 3° to 40°, scanning step size of 0.02°, scanning speed of 4° / min, and record the full spectrum diffraction data.

[0080] (3) Take about 3 mg of each sample, place them in a standard aluminum crucible and cover them tightly. Make microholes in the crucible cover and place it in the heating cell of the differential scanning calorimeter.

[0081] (4) Using an empty aluminum crucible as a reference, high-purity nitrogen was used as the purge gas at a flow rate of 50 mL / min. The heating program was set to start from 30 °C and linearly heat to 250 °C at a heating rate of 10 °C / min, and the DSC heat flow signal was recorded.

[0082] (5) Export the XRPD characteristic peak positions, relative crystallinity, and the onset and peak temperatures of the main endothermic peaks in the DSC curves for all samples, and summarize and organize the comparative data. The relative crystallinity of each sample was calculated using the same reference sample, the same integration interval, and the same background subtraction and data processing conditions.

[0083] The experimental results are shown in Table 1: Table 1: Characteristic data of XRPD diffraction peaks and main endothermic peaks of DSC for products from Examples 1 to 5 and Comparative Example 1

[0084] in conclusion: According to Table 1 and Figure 1The test data show that the products obtained in Examples 1 to 5 all exhibit consistent and sharp characteristic diffraction peaks near 2θ of 6.5°, 9.2°, 13.8°, 18.5°, and 22.1°, with a relative crystallinity all exceeding 97.5%. The DSC curves all show a single, sharp main endothermic peak with an initial temperature of approximately 172°C and a peak temperature of approximately 175°C. The data demonstrate that the controllable crystallization method of this invention can stably produce a target stable crystal form with high relative crystallinity and consistent crystal structure under different process parameters and industrial scales.

[0085] In contrast, Comparative Example 1, due to the absence of polyvinylpyrrolidone K17, the lack of a nonlinear antisolvent dropwise addition procedure, and the absence of reduced-pressure azeotropic dehydration, exhibited significant liquid-liquid phase separation and non-uniform precipitation during its crystallization process. Its XRPD spectrum showed marked broadening of diffraction peaks near 14.15° and 21.84°, the absence of the main peak near 18.5°, and the appearance of distinct amorphous diffuse peaks in the 15° to 25° range. Simultaneously, the relative crystallinity decreased to 82.3%, and the main endothermic peaks in the DSC shifted towards lower temperatures and broadened in shape.

[0086] The above results indicate that when the aforementioned process control measures are lacking, the crystal growth process is prone to crystallization defects, an increase in amorphous components, and a higher risk of mother liquor entrainment and impurity inclusion. The relative crystallinity and thermal characteristics of the resulting product are significantly inferior to those of the example. These results verify the effectiveness of the combined process of this invention in improving the relative crystallinity and crystal form consistency of the target stable crystal form.

[0087] The target stable crystal form of derafloxacin meglumine salt refers to a crystal form with characteristic diffraction peaks at approximately 6.5°, 9.2°, 13.8°, 18.5°, 22.1°, and 26.4° in the X-ray powder diffraction pattern measured by Cu-Kα radiation, and with the onset temperature of the main endothermic peak in DSC being approximately 172°C and the peak temperature being approximately 175°C. The term "stable" means that the crystal form can maintain its crystal form consistency under the conditions of the preparation, separation, and drying processes described above.

[0088] Test Example 2: Test objective: To verify the inhibitory effect of the polyvinylpyrrolidone K17 synergistic solvent system on liquid phase separation during the crystallization nucleation stage.

[0089] Experimental steps: (1) Select a crystallization reaction system with data acquisition function, and connect a high-precision online torque sensor with a range of 0 to 10 N·m in series on the drive shaft of the stirring motor of the reactor. At the same time, install an immersion fiber optic transmittance measuring probe in the reactor, with the optical path set to 10 mm.

[0090] (2) The experimental subjects were set as Example 1 and Comparative Example 2, and the preparation process was started according to the raw material ratio, temperature control and solvent drop parameters set by each subject.

[0091] (3) The moment when the system reaches a homogeneous solution state and the ethyl acetate antisolvent is added dropwise is recorded as the test starting point, i.e. t=0. The stirring shaft torque signal and the solution transmittance signal are continuously recorded by the synchronous data acquisition card at a sampling frequency of 1Hz.

[0092] (4) Monitor continuously for 240 min from the start of adding ethyl acetate antisolvent. The monitoring range includes the first stage of antisolvent addition, the isothermal crystal growth stage after the seed crystal is added, and the first 60 min after the start of the second stage of nonlinear antisolvent addition. Extract the characteristic values ​​of key time nodes and export the corresponding monitoring curve data.

[0093] The experimental results are shown in Table 2: Table 2: Changes in process parameters at different stages of crystallization in Example 1 and Comparative Example 2

[0094] in conclusion: According to Table 2 and Figure 2 The test data for Comparative Example 2 showed that in the initial stage of antisolvent addition, the transmittance decreased rapidly, and the stirring shaft torque exhibited an abnormal peak value between 60 and 90 minutes, reaching a maximum of 4.62 N·m. These data characteristics indicate that a high-viscosity oil phase was formed in the system when the supersaturation increased, which increased fluid resistance and caused light scattering, indicating that liquid-liquid phase separation occurred in the system.

[0095] In Example 1, during the monitored antisolvent addition and isothermal crystal growth period, the stirring shaft torque did not show any sharp abrupt change, but only increased gradually with the gradual formation of suspended crystals, eventually stabilizing at around 1.89 N·m; at the same time, its transmittance curve showed a gradual downward trend, with no obvious abnormal optical fluctuations observed.

[0096] The above data indicate that, under the segmented dropwise addition and isothermal crystal growth process used in this embodiment, the addition of polyvinylpyrrolidone K17 resulted in a smoother change in the torque and transmittance of the system, and the formation of the oil phase was significantly suppressed. Based on the structural characteristics of polyvinylpyrrolidone K17, it is speculated that this effect may be related to its hydration state in the aqueous solvent system, hydrogen bonding interactions, and steric hindrance.

[0097] Test Example 3: Test objective: To verify the effect of nonlinear antisolvent addition procedure on secondary nucleation of the crystallization system and the final particle size distribution of the product.

[0098] Experimental steps: (1) The dried powders prepared in Example 1 and Comparative Example 3 were selected as test objects. Approximately 1.5g of each sample was weighed and stored at room temperature for later use.

[0099] (2) Turn on the laser particle size analyzer and configure the dry powder injection module. Set the optical parameters such as refractive index in the software operation interface and clear the test background to zero.

[0100] (3) Set the dispersion pressure of the test unit to 0.15MPa, the feed rate of the sampler vibrating plate to 50%, and the airflow shading degree to be controlled within the effective range of 2% to 8%.

[0101] (4) Add the weighed sample evenly into the sample funnel, start the continuous test program, and record the forward and side light scattering signals through the detector.

[0102] (5) By analyzing the volume reference particle size distribution data, extract the characteristic particle size parameters D10, D50 and D90, calculate the particle size distribution span value Span, and derive the volume reference particle size distribution curve.

[0103] The experimental results are shown in Table 3: Table 3: Powder particle size distribution characteristics of the products of Example 1 and Comparative Example 3

[0104] in conclusion: According to Table 3 and Figure 3 Based on the test data, the volumetric particle size distribution curve of Example 1 exhibits a unimodal, approximately log-normal distribution with a D50 of 85.62 μm and a span of 1.47, indicating a narrow and concentrated particle size distribution. In contrast, the distribution curve of Comparative Example 3 shows additional fine-diameter peaks in the smaller particle size range, exhibiting an overall bimodal particle size distribution with a D10 decreasing to 5.21 μm and a span expanding to 4.28.

[0105] The above results indicate that in Comparative Example 3, during the constant flow rate of adding antisolvent, the surface area of ​​the existing crystals was insufficient to consume the continuously forming supersaturation, leading to the accumulation of supersaturation and exceeding the critical condition for secondary nucleation in the metastable region of the system, thus resulting in explosive secondary nucleation and the generation of a large number of fine crystals.

[0106] Example 1 employs a nonlinear antisolvent dropping program in which the cumulative volume of the second part of ethyl acetate increases according to a cubic function of the dropping time of the second part of ethyl acetate. The dropping rate is slow in the early stage and gradually increases in the later stage, so that the rate of supersaturation formation matches the gradually increasing surface area of ​​the crystals in the reactor. This is beneficial to control the relative supersaturation of the system within the metastable region, suppress secondary nucleation, and allow the solute to preferentially deposit on the surface of the existing crystals.

[0107] The above data shows that the nonlinear antisolvent dropping procedure, in which the cumulative volume of the second batch of ethyl acetate increases according to the cubic function of the dropping time of the second batch of ethyl acetate, is beneficial to reduce the formation of fine powder and improve the concentration of product particle size distribution.

[0108] Test Example 4: Test objective: To verify the effect of nitrogen-assisted bubbling and ethyl acetate phase reflux under reduced pressure azeotropic dehydration on the residual amount of PVP K17 and the area-normalized purity of the principal component in the final product.

[0109] Experimental steps: (1) The dried powders prepared in Example 1, Comparative Example 1 and Comparative Example 4 were selected as test samples, and a certain mass was weighed for subsequent testing.

[0110] (2) Take about 20 mg of each sample and place it in a 50 mL volumetric flask. Dissolve and dilute the sample with a mixture of 0.1% trifluoroacetic acid aqueous solution and acetonitrile. Filter the solution through a 0.45 μm microporous membrane to obtain the test solution for high performance liquid chromatography detection.

[0111] (3) A high-performance liquid chromatograph equipped with an ultraviolet detector was used, a C18 reversed-phase column was selected, the detection wavelength was set to 275 nm, the chromatogram was recorded, and the area normalization purity of the main component of derafloxacin meglumine salt and the maximum single impurity content were calculated by the area normalization method.

[0112] (4) Take about 2.0g of each sample and dissolve them in 20mL of purified water. Add 2mL of 0.1mol / L citrate-phosphate buffer and 1mL of 0.005mol / L iodine-potassium iodide colorimetric solution in sequence. Shake well and let stand for 15min in the dark.

[0113] (5) Using a UV-Vis spectrophotometer, with a mixture of purified water and chromogenic reagent as a blank reference, continuous scanning was performed in the wavelength range of 400 nm to 700 nm to record the full-wavelength absorption spectrum curve. The characteristic absorbance value near 500 nm was extracted and combined with the PVP K17 standard curve verified by linearity, precision, and spike recovery rate to calculate the residual amount of PVPK17 in each sample. If the sample response value exceeded the linear range of the standard curve, it was re-measured after appropriate dilution.

[0114] The experimental results are shown in Table 4: Table 4: Main component area-normalized purity and PVP K17 residue of products from Example 1, Comparative Example 1 and Comparative Example 4

[0115] in conclusion: According to Table 4 and Figure 4 The test data for Comparative Example 1 showed that since no polyvinylpyrrolidone K17 was added during the preparation process, it did not show obvious characteristic absorption at 500 nm. However, liquid-liquid phase separation occurred in the system, resulting in a large amount of mother liquor components being entrained or trapped during the non-uniform solidification process. The final normalized purity of the main component area was 98.23%.

[0116] Comparative Example 4 added polyvinylpyrrolidone (PVP) K17 to the crystallization system, but did not perform azeotropic dehydration under reduced pressure in the later stage of crystallization. After colorimetric reaction, the sample showed a broad absorption band at 500 nm, and the calculated residual PVP K17 content was 4126.8 ppm. Simultaneously, the area-normalized purity of the main component decreased to 97.45%, and the maximum single impurity content increased to 1.84%. These results indicate that without azeotropic dehydration under reduced pressure, PVP K17 is easily adsorbed on the crystal surface or trapped within the crystals, potentially increasing the retention of other mother liquor components in the solid phase.

[0117] Example 1 underwent nitrogen-assisted bubbling and ethyl acetate phase reflux dehydration under reduced pressure azeotropic dehydration. The absorbance curve of the final product was close to the blank baseline, the residual PVP K17 decreased to 43.5 ppm, which was lower than that of Comparative Example 4, and the area normalized purity of the principal component increased to 99.82%.

[0118] The above data indicate that reduced-pressure azeotropic dehydration can reduce the residual amount of PVP K17 in the product and decrease the residue of other mother liquor components in the solid phase. It is speculated that this is because the reduced water content alters the hydration state and molecular conformation of PVP K17, weakening its interaction with the crystal surface. This facilitates the desorption of PVP K17 from the crystal surface and its entry into the mother liquor. This operation maintains the crystal morphology of the product while reducing the risk of adsorption and encapsulation of PVP K17 on the crystal surface.

[0119] Test Example 5: Test objective: To verify the effects of nitrogen bubbling assistance and ethyl acetate phase reflux during the dehydration stage on the temperature, pressure, operational stability of the dehydration process, and final product yield of the reaction system.

[0120] Experimental steps: (1) Select a crystallization reaction system with DCS historical data storage function, extract the sensor data of step (4) in the preparation process of Example 1, Example 5 and Comparative Example 5, and test the slurry in the system.

[0121] (2) At the start of the dehydration operation, i.e. the moment when the pressure reduction program begins, the record start point is recorded. The absolute pressure data and material temperature data in the reactor are continuously collected within 60 minutes. The time series record file is exported to analyze the parameter fluctuation range.

[0122] (3) After the crystallization process is completed and the slurry is discharged, add 500 mL of anhydrous ethanol to each reactor. In Example 5, 50 L of anhydrous ethanol is used to wash off the residual solids adhering to the reactor wall and the agitator. Collect the eluent and dry it by rotary evaporation. Weigh the dry product to calculate the solids adhering to the reactor wall and the agitator.

[0123] (4) Collect the target stable crystal form dry powder obtained after separation, washing and vacuum drying, weigh it and calculate the actual yield of each batch of crystallized products in combination with the mass of raw materials input.

[0124] (5) Integrate the extreme value data of the sensor, the solid adhesion loss rate of the vessel wall and the agitator, and the yield calculation results to make a parameter comparison table.

[0125] The experimental results are shown in Table 5: Table 5: Comparison of operational stability and yield of the dehydration process between the examples and comparative examples.

[0126] in conclusion: According to Table 5 and Figure 5 The test data for Comparative Example 5 showed that the solvent was directly removed through a vacuum system. This system lacked a stable gas-liquid interface and vaporization nucleation sites, making it prone to localized overheating after reaching its boiling point, followed by sudden flash evaporation. A large amount of solvent vaporized instantaneously and absorbed the latent heat of vaporization, causing a pressure fluctuation of 34.6 kPa and a temperature fluctuation of 12.8 °C within the reactor. Simultaneously, due to the lack of ethyl acetate reflux, the liquid phase volume decreased significantly, and the supersaturation increased rapidly. Material entrainment and the formation of numerous fine crystals resulted in a significant amount of solid adhering to the reactor wall and the surface of the agitator, with a solid adhesion loss rate of 18.73% and a final product yield of 71.82%.

[0127] In Example 1 and the industrial-scale Example 5, nitrogen is continuously introduced through a bottom gas distributor, and a large number of microbubbles provide a continuous gas-liquid interface, reducing the risk of local overheating and sudden flash evaporation of the liquid; at the same time, the condensate is separated and the ethyl acetate phase is continuously refluxed through a water separator.

[0128] During the test, the system temperature remained stable around the set value, and the absolute pressure decreased smoothly according to the programmed settings, without significant boiling or material entrainment. Continuous reflux of the ethyl acetate phase reduced the net loss of organic solvent and the resulting abrupt changes in slurry concentration, thereby reducing the risk of drastic fluctuations in supersaturation. The solid adhesion loss rates on the vessel wall and agitator in Examples 1 and 5 were both less than 1.5%, and the crystallization yields were both greater than 91.5%.

[0129] The test data above show that combining nitrogen bubbling with ethyl acetate phase reflux is beneficial to improving the operational stability of the dehydration process and reducing the loss of solids adhering to the equipment surface.

[0130] Test Example 6: Test objective: To comprehensively evaluate the effects of different process conditions on the filtration performance of the crystallized product, the weight loss of the filter cake at 105℃, and the final powder flowability.

[0131] Experimental steps: (1) After each batch of constant temperature heat preservation is completed, keep the slurry fully stirred, take representative slurry samples from the reaction systems of Examples 1 to 5 and Comparative Examples 1 to 5 respectively, and accurately measure 1.0L as the filtration test object, and record the solid content of each sample.

[0132] (2) A solid-liquid separation device was assembled using a standard Buchner funnel and a vacuum filtration flask. A polytetrafluoroethylene microporous filter membrane with a pore size of 30 μm was laid, and the vacuum degree was set to a constant -0.08 MPa. A 1.0 L sample of slurry was poured into the Buchner funnel for filtration. The time from the start of filtration until no continuous mother liquor layer was present on the surface of the filter cake was recorded to obtain the filtration time per unit volume of slurry. All samples were tested under the same filtration area, the same vacuum degree, and comparable solid content.

[0133] (3) Randomly sample from different parts of the filter cake after filtration, totaling about 10g, and place them in the aluminum foil tray of the infrared moisture analyzer. Set the heating temperature to 105℃ and use constant weight mode to test the 105℃ drying loss of the filter cake.

[0134] (4) Take each batch of powder samples after complete vacuum drying and let them stand for 24 hours in a constant temperature and humidity environment of 25℃ and 45% relative humidity to reduce the influence of static electricity on the test results.

[0135] (5) After the powder sample has been left to stand, it is placed into the fixed funnel of the powder comprehensive characteristic tester. The vibration feeding module is turned on so that the powder falls freely onto the measuring disk to form a powder cone. The repose angle of the powder cone is measured using the optical imaging system of the instrument. The above parameters are integrated to generate a comparison record.

[0136] The experimental results are shown in Table 6: Table 6: Test data on filtration performance and powder engineering properties of the products from the examples and comparative examples.

[0137] in conclusion: According to Table 6 and Figure 6The test data showed that the filtration time per unit volume of slurry in Comparative Examples 1 to 3 all exceeded 180 s / L, with the highest reaching 256.4 s / L. The weight loss of the separated filter cake after drying at 105℃ was in the range of 31% to 40%, and the angle of repose of the powder was greater than 48°.

[0138] Comparative Examples 1 and 2, lacking the addition of polyvinylpyrrolidone K17, were more prone to oil phase precipitation and non-uniform precipitation. While Comparative Example 3 included polyvinylpyrrolidone K17, the constant flow rate of the residual antisolvent led to supersaturation accumulation and the formation of numerous secondary crystal nuclei. Regarding the unit volume filtration time, filter cake weight loss at 105°C, and powder angle of repose listed in Table 6, secondary nucleation directly increased the proportion of fine crystals. Therefore, Comparative Example 3 performed worse than Comparative Example 1 in these powder engineering indicators. Furthermore, Comparative Example 1, lacking polyvinylpyrrolidone K17, non-linear antisolvent addition, and reduced-pressure azeotropic dehydration, still exhibited significantly inferior overall quality indicators such as relative crystallinity and main component purity compared to the examples. Therefore, the lower filtration and flowability indicators of Comparative Example 3 compared to Comparative Example 1 in Table 6 are not contradictory to the different emphases of the impact of missing process factors on various evaluation indicators.

[0139] Fine particles have a large specific surface area and surface energy, which leads to a decrease in filter cake porosity and blockage of microporous filter membranes in the early stage of filtration, thereby increasing fluid permeation resistance. The capillary forces between fine particles cause more mother liquor to be retained inside the filter cake, resulting in an increase in the filter cake's weight loss at 105℃. After drying, the strong van der Waals forces between fine powders make the particles prone to agglomeration and clumping, which is macroscopically manifested as an increased angle of repose.

[0140] In Comparative Example 4, since no depressurized azeotropic dehydration was performed, the product surface had residual polyvinylpyrrolidone K17 that was not fully desorbed, which increased the hygroscopicity and adhesion of the powder, resulting in poor flowability of the dried powder and an angle of repose of 43.8°.

[0141] Examples 1 to 5, through suppressing oil precipitation, employing a nonlinear antisolvent dropping procedure, and performing reduced-pressure azeotropic dehydration, yielded products with regular crystal morphology and concentrated particle size distribution, reducing fine powder inclusions and agglomeration. The regularly grown crystals formed uniform and interconnected filter cake channels during solid-liquid separation, significantly reducing filtration resistance and filtration time to 38.6 s / L to 45.4 s / L; the mother liquor was effectively discharged, reducing the filter cake drying weight loss at 105°C to approximately 15% or less. Simultaneously, with reduced PVP K17 residue, the dried powder exhibited good free flowability, maintaining a low angle of repose of 31° to 35°.

[0142] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. A method for the controlled crystallization preparation of a stable crystal form of derafloxacin meglumine salt, characterized in that, Includes the following steps: (1) Mix dimethyl sulfoxide with purified water evenly, add delafloxacin free acid and meglumine, heat and stir at a constant temperature until a clear homogeneous solution is formed; then add polyvinylpyrrolidone K17 and continue stirring until polyvinylpyrrolidone K17 is completely dissolved. (2) Maintain the system temperature of step (1), add the first part of ethyl acetate antisolvent to the reactor at a constant flow rate until the system appears opalescent, add the target stable crystal form micronized seed crystal of derafloxacin meglumine salt, stop adding antisolvent and carry out constant temperature crystal growth; (3) Maintain the system temperature and add the remaining second part of ethyl acetate dropwise through a nonlinear antisolvent dropwise program. Control the ratio of the cumulative volume of the second part of ethyl acetate added to the total volume of the second part of ethyl acetate added to be equal to the cube of the ratio of the current dropwise time of the second part of ethyl acetate to the total dropwise time of the second part of ethyl acetate. (4) After the addition is completed, nitrogen gas is continuously introduced from the bottom of the reactor to bubble the gas phase, while the pressure inside the reactor is gradually reduced to a vacuum state, so that the system undergoes depressurized azeotropic dehydration; after the azeotropic vapor is condensed and separated by a water separator, the bottom water phase is discharged, and the upper ethyl acetate phase is continuously refluxed into the reactor to maintain a constant liquid level in the system. When the water mass fraction of the liquid phase in the reactor drops to 0.10wt% to 0.25wt%, the vacuum is released. (5) The system is linearly cooled to the set temperature and kept at that temperature. Then the suspension slurry is separated into solid and liquid, the filter cake is washed, and finally dried to obtain the target stable crystal form of derafloxacin meglumine salt.

2. The method for controllable crystallization preparation of the stable crystal form of derafloxacin meglumine salt according to claim 1, characterized in that, In step (1), for every 100g of derafloxacin free acid added, the amount of dimethyl sulfoxide added is 425g to 600g, the amount of purified water added is 75g to 200g, the amount of meglumine added is 44.8g to 46.5g, and the amount of polyvinylpyrrolidone K17 added is 0.1g to 0.3g.

3. The method for controllable crystallization preparation of the stable crystal form of derafloxacin meglumine salt according to claim 1, characterized in that, In step (1), the heating rate is 1.5℃ / min to 2.0℃ / min, the constant temperature stirring temperature is 60℃ to 70℃, the constant temperature stirring time is 1.0h to 2.0h, and the stirring time after adding polyvinylpyrrolidone K17 is 20min to 40min.

4. The method for controllable crystallization preparation of the stable crystal form of derafloxacin meglumine salt according to claim 1, characterized in that, In step (2), for every 100g of derafloxacin free acid added, the volume of the first part of ethyl acetate antisolvent added is 120mL to 600mL, the constant flow rate is 2.5mL / min to 6.6mL / min, the amount of derafloxacin meglumine salt target stable crystal micronized seed added is 0.7g to 2.8g, and the constant temperature crystal growth time is 1.5h to 3.0h.

5. The method for controllable crystallization preparation of the stable crystal form of derafloxacin meglumine salt according to claim 1, characterized in that, In step (3), for every 100g of derafloxacin free acid added, the total volume of the second part of ethyl acetate added is 1080mL to 2400mL, and the total dropping time of the second part of ethyl acetate is controlled to be 3.0h to 5.0h; the cumulative volume of the second part of ethyl acetate added = the total volume of the second part of ethyl acetate added × (the current dropping time of the second part of ethyl acetate ÷ the total dropping time of the second part of ethyl acetate) 3 .

6. The method for controllable crystallization preparation of the stable crystal form of derafloxacin meglumine salt according to claim 1, characterized in that, In step (4), the continuous nitrogen flow rate is controlled from 0.02vvm to 0.10vvm, the rate of gradual pressure reduction in the reactor is controlled from 1.0kPa / min to 3.0kPa / min, the absolute pressure range maintained during the depressurized azeotropic dehydration process is from 60kPa to 70kPa, and the set endpoint for the liquid phase water content is from 0.10wt% to 0.25wt%.

7. The method for controllable crystallization preparation of the stable crystal form of derafloxacin meglumine salt according to claim 1, characterized in that, In step (5), the linear cooling rate of the system is 5℃ / h to 15℃ / h, the set temperature is 0℃ to 10℃, and the holding time is 1.0h to 2.0h; for every 100g of derafloxacin free acid added, the filter cake is washed with 200mL to 500mL of cold ethyl acetate each time, and the number of washing times is 2 to 3; the drying is carried out under vacuum at a temperature of 40℃ to 50℃, with an absolute pressure of less than 5kPa, and the vacuum drying time is 6.0h to 10.0h.

8. The method for controllable crystallization preparation of the stable crystal form of derafloxacin meglumine salt according to claim 1, characterized in that, The median particle size D50 of the micronized seed crystals of the target stable crystal form of derafloxacin meglumine salt described in step (2) is 5.2 μm to 12.8 μm.

9. The method for controlled crystallization preparation of the stable crystal form of derafloxacin meglumine salt according to any one of claims 1-8, characterized in that, The preparation steps of the micronized seed crystals of the target stable crystal form of derafloxacin meglumine salt in step (2) include: Mix dimethyl sulfoxide with purified water until homogeneous, add derafloxacin free acid and meglumine, and stir at a constant temperature of 60°C to 70°C until a clear homogeneous solution is formed. Under constant temperature and constant stirring speed, ethyl acetate was added dropwise to a homogeneous solution at a uniform rate. After the addition was completed, the cooling rate was controlled at 5℃ / h to 15℃ / h. The temperature was lowered to 0℃ to 10℃ and kept at the temperature while stirring to obtain a suspension. The suspension was centrifuged to separate solids from liquids, dried, and pulverized to obtain micronized seed crystals of the target stable crystal form of derafloxacin meglumine salt.

10. The method for controllable crystallization preparation of the stable crystal form of derafloxacin meglumine salt according to claim 9, characterized in that, The suspension was centrifuged to separate solid and liquid components. The filter cake was washed with cold ethyl acetate at a temperature of 0°C to 10°C. The washed filter cake was then continuously vacuum dried at 40°C to 50°C and an absolute pressure of less than 5 kPa for 8.0 h to 12.0 h. The vacuum-dried material was then transferred to a pulverizing device for micronization. The collected micronized powder was the target stable crystal form micronized seed crystal of derafloxacin meglumine salt.